Could Twice-Daily insulin shots improve pregnancy outcomes for diabetic moms?

NCT ID NCT07224893

Recruiting now Disease control Sponsor: Eastern Virginia Medical School Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares taking insulin glargine once versus twice daily in pregnant women with type 2 diabetes who need insulin. Two hundred participants will be randomly assigned to one of the two dosing schedules, and their blood sugar levels will be tracked continuously. The goal is to see if twice-daily dosing leads to better blood sugar control and fewer pregnancy complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: insulin glargine
What this could lead to: If successful, this could show that a simple change in dosing schedule improves blood sugar control and pregnancy outcomes for women with pre-existing diabetes.
What could go wrong: This is a small, early-phase trial (200 participants) comparing two common dosing schedules, so the difference may be small or not clinically meaningful. Results may not apply to all types of diabetes or pregnancies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREGESTATIONAL DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gestational diabetes type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PREGESTATIONAL DIABETES PREGNANCY

Contacts and locations

Locations

Sentara Norfolk General Hospital, Norfolk, Virginia 23507
RECRUITING

Norfolk, Virginia, 23507, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.